Dtsch Med Wochenschr 2004; 129: S63-S65
DOI: 10.1055/s-2004-831374
Kurzübersicht
Leber
© Georg Thieme Verlag Stuttgart · New York

Aszites - Diagnostik und Therapie

Diagnosis and treatment of ascitesA. L. Gerbes1 , V. Gülberg1
  • 1Medizinische Klinik II, Klinikum der Ludwig-Maximilians-Universität - Großhadern, München
Further Information

Publication History

eingereicht: 5.5.2004

akzeptiert: 13.8.2004

Publication Date:
15 September 2004 (online)

Glossar

ADH = Antidiuretisches Hormon

HRS = hepatorenales Syndrom

RAAS = Renin-Angiotensin-Aldosteronsystem

SNS = sympathisches Nervensystem

SBP = spontane bakterielle Peritonitis

TIPS = transjugulärer intrahepatischer portosystemischer Shunt

Literatur

  • 1 Angeli P, Volpin R, Gerunda G. et al . Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.  Hepatology. 1999;  29 1690-1697
  • 2 Arroyo V, Gines P, Gerbes A L. et al . Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.  Hepatology. 1996;  23 164-176
  • 3 Brensing K A, Textor J, Perz J. et al . Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.  Gut. 2000;  47 288-295
  • 4 Ginès A, Escorsell A, Ginès P. et al . Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.  Gastroenterology. 1993;  105 229-236
  • 5 Gines P, Tito L, Arroyo V. et al . Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.  Gastroenterology. 1988;  94 1493-1502
  • 6 Gonwa T A, Klintmalm G B, Levy M. et al . Impact of pretransplant renal function on survival after liver transplantation.  Transplantation. 1995;  15 (59) 361-365
  • 7 Gülberg V, Bilzer M, Gerbes A L. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.  Hepatology. 1999;  30 870-875
  • 8 Gülberg V, Gerbes A L. Diagnostik und Therapie des Aszites bei Leberzirrhose.  Internist (Berl.). 1998;  39 254-262
  • 9 Gülberg V, Liss I, Bilzer M. et al . Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts.  Digestion. 2002;  66 127-130
  • 10 Moreau R, Durand F, Poynard T. et al . Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.  Gastroenterology. 2002;  122 923-930
  • 11 Restuccia T, Ortega R, Guevara M. et al . Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.  J Hepatol. 2004;  40 140-146
  • 12 Rössle M, Ochs A, Gülberg V. et al . A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.  N Engl J Med. 2000;  342 1701-1707
  • 13 Schrier R W, Arroyo V, Bernardi M. et al . Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.  Hepatology. 1988;  8 1151-1157
  • 14 Sort P, Navasa M, Arroyo V. et al . Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.  N Engl J Med. 1999;  341 403-409

Prof. Dr. med. Alexander L. Gerbes

Ludwig-Maximilians-Universität München, Medizinische Klinik II

Marchioninistraße 15

81366 München

Phone: (0 89) 70 95-22 92

Fax: (0 89) 70 95-23 92

Email: gerbes@med2.med.uni-muenchen.de

    >